Another Fatty Liver Idea. This Time a Play on Detecting Fatty Liver Non-Invasively. Heads Up. Nearing Resistance at $0.89.
Excess fat in the liver (steatosis) is the root cause of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which affect more than 1 billion people globally.
They closed a smallish $5 million secondary in late December.
We came across ENDRA while doing research on the fatty liver problem affecting up to 25% of the US population. This is a huge problem that can lead to cirrhosis of the liver, whether you’re a drinker or not. Like diabetes, this is a hidden killer with few symptoms. Unlike diabetes, it cannot be easily detected using a simple blood test.
ENDRA is looking to change that.
Not many details forthcoming other than to say we think this is an opportune time, in that it is nearing a breakout, after a very difficult 2020. There should be enough information below to make an intelligent decision!
TAEUS® is a new, proprietary way to measure fat in the liver that is now CE-marked for sale in Europe. The technology is non-invasive and costs 50x less than MRI. TAEUS® works with any B-mode ultrasound machine, but it does what ultrasound alone cannot do: Measure steatosis (liver fat) and early staging of NAFLD/NASH.
TAEUS® uses a unique, groundbreaking combination of radio frequency and ultrasound to characterize human tissue in a way similar to MRI—at 50x lower cost, and at the point of patient care.
“If we could diagnose NAFLD-NASH early in the disease cycle, while it is still reversible, with a tool that is safe and easily accessible at the point of patient care, it could improve the health of millions of people and dramatically lower healthcare costs associated with later-stage acute disease management. ENDRA’s Thermo Acoustic Enhanced Ultrasound® (TAEUS®) liver device could be a game changer in the clinical care cycle of liver disease.”
— Sam Gambhir, M.D, Ph.D
Chair, Dept. of Radiology and Director, Molecular Imaging Program, Stanford University
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visitwww.endrainc.com.
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS® device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration regulatory approval and expectations concerning ENDRA’s business strategy. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA’s filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
Chief Financial Officer